Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

At times of personalized and individualized medicine the concept of randomized- controlled clinical trials (RCTs) is being questioned. This review article explains principles of evidence-based medicine in oncology and shows an example of how evidence can be generated independently from RCTs. Persona...

Full description

Bibliographic Details
Main Authors:	Volker Schirrmacher, Tobias Sprenger, Wilfried Stuecker, Stefaan W. Van Gool
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Biomedicines
Subjects:	randomized-controlled trial evidence-based medicine conflict of interest adverse events cancer immunology immunotherapy
Online Access:	https://www.mdpi.com/2227-9059/8/8/237

Similar Items

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
by: Volker Schirrmacher, et al.
Published: (2022-10-01)

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
by: Stefaan W. Van Gool, et al.
Published: (2020-12-01)

The SMART Safety: An empirical dataset for evidence synthesis of adverse events
by: Shiqi Fan, et al.
Published: (2023-12-01)

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
by: Volker Schirrmacher, et al.
Published: (2019-08-01)

The Application of Evidence-Based Medicine in Individualized Medicine
by: Peter Van de Vliet, et al.
Published: (2023-06-01)

Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
by: Stefaan W. Van Gool, et al.
Published: (2023-02-01)

Adverse Events of Oncologic Immunotherapy and Their Management
by: Fedricker Diane Barber
Published: (2019-01-01)

Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn’t!
by: Kaveh Zakeri, et al.
Published: (2018-04-01)

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
by: Christopher Cluxton, et al.
Published: (2023-07-01)

DISCUSSION IDEAS ABOUT MEDICINE AMBIGUITIES
by: Yu. V. Muravyev, et al.
Published: (2017-10-01)

Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit
by: Adrien Joseph, et al.
Published: (2020-10-01)

Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited
by: Lee eBlack, et al.
Published: (2013-03-01)

Financial Conflicts of Interest Change After a High-Impact Clinical Trial Publication in Oncology
by: Craig L. Cambridge, et al.
Published: (2020-07-01)

Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee
by: Paul J. Turner, MD, PhD, et al.
Published: (2024-03-01)

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
by: Elena Verzoni, et al.
Published: (2019-04-01)

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
by: Jean-Matthieu L’Orphelin, et al.
Published: (2021-09-01)

Efficacy and safety of Tripterygium glycosides as an add-on treatment in adults with chronic urticaria: a systematic review and meta-analysis
by: Ming Li, et al.
Published: (2023-12-01)

Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
by: Luciano Hollanda, et al.
Published: (2014-12-01)

The Adverse Event Paradox
by: Thomas Milovac
Published: (2022-05-01)

Therapeutic novelties in migraine: new drugs, new hope?
by: Thien Phu Do, et al.
Published: (2019-04-01)

Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials
by: Xinyi Wang, et al.
Published: (2022-08-01)

On the safety and effectiveness of COVID-19 vaccines, certainties and uncertainties
by: Ana Cecilia Amado Xavier de Oliveira, et al.
Published: (2021-08-01)

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
by: Laura Kalfeist, et al.
Published: (2022-02-01)

Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study
by: Achalu DL, et al.
Published: (2023-11-01)

Methods for the Inclusion of Real-World Evidence in a Rare Events Meta-Analysis of Randomized Controlled Trials
by: Minghong Yao, et al.
Published: (2023-02-01)

CARDIOVASCULAR EVENT RISK REDUCTION WITH MEDICINES: DATA OF EVIDENCE BASED MEDICINE AND RECOMMENDATIONS TO PRACTITIONERS
by: S. Y. Martsevich
Published: (2016-01-01)

Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
by: Stefaan W. Van Gool, et al.
Published: (2020-05-01)

A comparison between conflict of interest in Western and Islamic literatures in the realm of medicine.
by: Mojtaba Parsa, et al.
Published: (2015-10-01)

Auricular acupressure for adverse events following immunization after COVID-19 vaccine injection: A multicentre, blinded, randomized controlled trial
by: Qinwei Fu, et al.
Published: (2022-12-01)

Adverse events of intestinal microbiota transplantation in randomized controlled trials: a systematic review and meta-analysis
by: Chong Chen, et al.
Published: (2022-05-01)

Evidence on conflicts of interest in medicine
by: Mario Arturo González-Mariño
Published: (2020-01-01)

Adverse events and nocebo phenomena: treatment or disease specific?
by: Panagiotis Zis, et al.
Published: (2019-02-01)

Venous thromboembolism prophylaxis may cause more harm than benefit: an evidence-based analysis of Canadian and international guidelines
by: Andrew Kotaska
Published: (2018-10-01)

Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials
by: Jennifer G. Le-Rademacher, et al.
Published: (2020-11-01)

The effect of a conflict of interest disclosure form using closed questions on the number of positive conflicts of interest declared – a controlled study
by: Christopher Baethge
Published: (2013-08-01)

Cutaneous Adverse Events to Targeted Therapies and Immunotherapies in Children: A Retrospective Study of 103 Patients from Two Tertiary Haemato-Oncology Referral Centres
by: Ayelet Ollech, et al.
Published: (2021-07-01)

An empirical comparison of the harmful effects for randomized controlled trials and non-randomized studies of interventions
by: Minhan Dai, et al.
Published: (2023-03-01)

Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram
by: Agnese Losurdo, et al.
Published: (2024-01-01)

Adverse effects associated with acupuncture therapies: An evidence mapping from 535 systematic reviews
by: Meng Xu, et al.
Published: (2023-04-01)

Big food and drink sponsorship of conferences and speakers: a case study of one multinational company’s influence over knowledge dissemination and professional engagement
by: Jónas Atli Gunnarsson, et al.
Published: (2023-05-01)